Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
07:05am, Thursday, 31'st Jul 2025
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its second quarter 2025 financial results and business highlights.
FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio
12:12pm, Tuesday, 29'th Jul 2025
The U.S. Food and Drug Administration approved on Monday Apellis Pharmaceuticals, Inc.'s APLS Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex memb
FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
07:19pm, Monday, 28'th Jul 2025
WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan)
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
07:00am, Thursday, 24'th Jul 2025
WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter
WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
11:36am, Wednesday, 02'nd Jul 2025
APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
07:35am, Tuesday, 01'st Jul 2025
STOCKHOLM , July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty oblig
WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $3
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?
12:37pm, Friday, 06'th Jun 2025
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VA
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
07:00am, Wednesday, 04'th Jun 2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Confere
Apellis Pharmaceuticals: Have Some Patience
09:28am, Tuesday, 20'th May 2025
Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slow
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
11:45am, Thursday, 08'th May 2025
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Why Apellis Pharmaceuticals Wilted on Wednesday
06:09pm, Wednesday, 07'th May 2025
A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and the
Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript
01:18pm, Wednesday, 07'th May 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder
